Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI

This publication has 13 references indexed in Scilit:

• Mucopolysaccharidosis VI
  Orphanet Journal of Rare Diseases, 2010
• Mechanism of Glycosaminoglycan-Mediated Bone and Joint Disease
  The American Journal of Pathology, 2008
• Management Guidelines for Mucopolysaccharidosis VI
  Pediatrics, 2007
• Enzyme replacement therapy in two patients with an advanced severe (Hurler) phenotype of mucopolysaccharidosis I
  European Journal of Pediatrics, 2006
• Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study
  The Journal of Pediatrics, 2006
• Direct Comparison of Measures of Endurance, Mobility, and Joint Function During Enzyme-Replacement Therapy of Mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome): Results After 48 Weeks in a Phase 2 Open-Label Clinical Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase
  Pediatrics, 2005
• Otorhinolaryngological manifestations of the mucopolysaccharidoses
  International Journal of Pediatric Otorhinolaryngology, 2005
• Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)
  The Journal of Pediatrics, 2004
• Replacement therapy in Mucopolysaccharidosis type VI: advantages of early onset of therapy
  Molecular Genetics and Metabolism, 2003
• Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI.
  Journal of Clinical Investigation, 1997